CareDx (NASDAQ: CDNA - Get Free Report) and CollPlant Biotechnologies (NASDAQ: CLGN - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings. Risk and Volatility CareDx has a beta of 2.38,

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to curb excessive Medicare payments and save taxpayers an estimated $1 billion annually.

Five stocks stand out for high efficiency, with strong receivables, asset, inventory and operating margin metrics.

CareDx, Inc. (NASDAQ: CDNA - Get Free Report)'s share price reached a new 52-week high on Monday. The stock traded as high as $55.21 and last traded at $53.7380, with a volume of 1203 shares. The stock had previously closed at $53.83. Analyst Ratings Changes A number of analysts recently commented on CDNA shares. Craig

AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.

COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.

Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.

Canada Pension Plan Investment Board purchased a new position in shares of CareDx, Inc. (NASDAQ: CDNA) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 52,800 shares of the company's stock, valued at approximately $1,505,000. Canada Pension Plan Investment Board owned 0.10%

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.